U.S. patent application number 17/189091 was filed with the patent office on 2021-06-24 for pharmaceutical formulation.
The applicant listed for this patent is F2G Limited. Invention is credited to Derek LAW, Graham Edward Morris SIBLEY.
Application Number | 20210186967 17/189091 |
Document ID | / |
Family ID | 1000005432685 |
Filed Date | 2021-06-24 |
United States Patent
Application |
20210186967 |
Kind Code |
A1 |
LAW; Derek ; et al. |
June 24, 2021 |
PHARMACEUTICAL FORMULATION
Abstract
A pharmaceutical composition suitable for oral administration
comprising particles of
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide is provided. Also provided is
a pharmaceutical composition suitable for parenteral administration
wherein the composition comprises
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide. The compositions are useful
in the treatment of fungal infection in a subject in need
thereof.
Inventors: |
LAW; Derek; (Manchester,
GB) ; SIBLEY; Graham Edward Morris; (Manchester,
GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
F2G Limited |
Manchester |
|
GB |
|
|
Family ID: |
1000005432685 |
Appl. No.: |
17/189091 |
Filed: |
March 1, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16303999 |
Nov 21, 2018 |
10973821 |
|
|
PCT/GB2017/051494 |
May 25, 2017 |
|
|
|
17189091 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/40 20130101;
A61P 31/10 20180101; A61K 31/506 20130101; A61K 9/0053 20130101;
A61K 47/34 20130101; A61K 9/19 20130101; A61K 47/32 20130101 |
International
Class: |
A61K 31/506 20060101
A61K031/506; A61P 31/10 20060101 A61P031/10; A61K 9/00 20060101
A61K009/00; A61K 9/19 20060101 A61K009/19; A61K 47/32 20060101
A61K047/32; A61K 47/34 20060101 A61K047/34; A61K 47/40 20060101
A61K047/40 |
Foreign Application Data
Date |
Code |
Application Number |
May 25, 2016 |
GB |
1609222.3 |
Claims
1. A pharmaceutical composition suitable for oral administration
wherein the composition comprises spray-dried particles of a
compound of Formula I or a pharmaceutically acceptable salt thereof
##STR00022##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide
2. A pharmaceutical composition according to claim 1 comprising
spray-dried particles of a compound of Formula I.
3. A pharmaceutical composition according to claim 1 or claim 2
wherein the compound of Formula I is substantially amorphous.
4. A pharmaceutical composition according to any one of the
preceding claims which further comprises one or more
excipients.
5. A pharmaceutical composition according to claim 4, wherein the
composition comprises the excipient hydroxypropyl methyl cellulose
acetate succinate (HPMCAS).
6. A pharmaceutical composition according to any one of claim 4 or
5 wherein the mass ratio of the compound of Formula I to excipient
is from 1:100 to 1:1.
7. A pharmaceutical composition according to any one of claims 4 to
6 wherein the mass ratio of the compound of Formula I to excipient
is from 1:15 to 1:2.
8. A pharmaceutical composition according to any one of the
previous claims wherein the particles are obtainable by
spray-drying from a solution comprising an organic solvent selected
from dichloromethane, methanol, and mixtures thereof.
9. A pharmaceutical composition according to any one of the
previous claims and further comprising one or more pharmaceutically
acceptable binders and/or carriers and/or excipients and/or
diluents and/or adjuvants.
10. A pharmaceutical composition according to any one of the
previous claims in the form of a solid oral dosage form.
11. A pharmaceutical composition according to any one of the
previous claims in the form of a liquid oral dosage form.
12. A pharmaceutical composition according to claim 11 wherein the
liquid oral dosage form further comprises a pharmaceutically
acceptable buffer having a pKa in the range 6.0 to 8.0.
13. A pharmaceutical composition according to claim 11 or claim 12
wherein the buffer is from 1 mM to 200 mM phosphate buffer and
wherein the composition is buffered to about pH 7.
14. A pharmaceutical composition suitable for parenteral
administration comprising (i) a compound of Formula I or a
pharmaceutically acceptable salt thereof, ##STR00023##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide (ii) cyclodextrin or modified
cyclodextrin, and (iii) polyethylene glycol.
15. A pharmaceutical composition according to claim 14 comprising:
from 10 wt % to 40 wt % of cyclodextrin or modified cyclodextrin;
and/or from 10 wt % to 40 wt % of polyethylene glycol.
16. A pharmaceutical composition according to claim 14 or claim 15
wherein the cyclodextrin or modified cyclodextrin is hydroxy propyl
beta cyclodextrin.
17. A pharmaceutical composition according to any of claims 14 to
16 wherein the polyethylene glycol is PEG300 or PEG400.
18. A pharmaceutical composition according to any one of claims 14
to 17 which further comprises polyvinyl pyrrolidone (Povidone).
19. A pharmaceutical composition according to any one of claims 14
to 18 wherein the compound of Formula I or the pharmaceutically
acceptable salt thereof is present at a concentration of from 1
mg/mL to 10 mg/mL.
20. A pharmaceutical composition according to any one of claims 14
to 19 which further comprises one or more pharmaceutically
acceptable carriers and/or excipients and/or diluents and/or
adjuvants.
21. A pharmaceutical composition according to any one of claims 14
to 20 comprising: 4 mg/mL (relative to the final volume of the
composition) of the compound of Formula I 25 wt % of hydroxy propyl
beta cyclodextrin; wt % of PEG400; 1 wt % of polyvinyl pyrrolidone
(Povidone); phosphoric acid in sufficient amount to adjust the pH
of the pharmaceutical composition to pH 5.0; and water to 100%.
22. A pharmaceutical composition according to any one of the
previous claims for use in a method of treatment of a human or
animal subject in need thereof.
23. A composition for use according to claim 22 wherein the
treatment comprises prevention of or treatment of fungal infection
in the subject.
24. A method of preventing or treating fungal infection in a human
or animal subject in need thereof, said method comprising
administering to the human or animal subject a therapeutically
effective amount of a pharmaceutical composition according to any
one of claims 1 to 21.
25. Use of a pharmaceutical composition according to any one of
claims 1 to 21 in the manufacture of a medicament for use in the
prevention or treatment of fungal infection in a human or animal
subject in need thereof.
26. A method of producing a pharmaceutical composition comprising a
compound of Formula I or a pharmaceutically acceptable salt thereof
##STR00024##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide wherein said method comprises
spray-drying a solution of the compound of Formula (I) or salt
thereof.
27. A method according to claim 26 comprising: i) dissolving one or
more excipients in a solvent; ii) adding the compound of Formula I
to the solution produced in step (i); and iii) spray drying the
solution produced in step (ii).
28. A method according to claim 27 wherein: the excipient is
hydroxypropyl methyl cellulose acetate succinate (HPMCAS); the
solvent is a mixture of dichloromethane and methanol, wherein the
volume ratio of dichloromethane to methanol is from 5:1 to 1:1; the
concentration of the excipient in the solvent is from 5% to 20%
w/v; and the compound of Formula I is added to the solution of the
excipient in the solvent to give a concentration of 0.5% to 10% by
mass.
29. A pharmaceutical composition suitable for oral administration
wherein the composition comprises substantially amorphous particles
of a compound of Formula I or a pharmaceutically acceptable salt
thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 16/303,999, filed on May 25, 2017, which is a
U.S. national phase application under 35 U.S.C. .sctn. 371 of
International Application No. PCT/GB2017/051494, filed on May 25,
2017, which claims priority benefit of British Patent Application
No. 1609222.3, filed on May 25, 2016, the disclosures of each of
which are hereby incorporated by reference in their entireties.
FIELD OF THE INVENTION
[0002] This invention relates to pharmaceutical formulations
comprising a pyrrole compound. Specifically, it relates to
pharmaceutical compositions which are suitable for oral
administration, to pharmaceutical compositions which are suitable
for parenteral administration, and to the use of such compositions
in prevention or treatment of fungal diseases. It also relates to a
method of producing a pharmaceutical composition as described
herein.
BACKGROUND OF THE INVENTION
[0003] Invasive fungal infections are well recognised as diseases
of the immunocompromised host. Over the last twenty years there
have been significant rises in the number of recorded instances of
fungal infection. In part this is due to increased awareness and
improved diagnosis of fungal infection. However, the primary cause
of this increased incidence is the vast rise in the number of
susceptible individuals. This is due to a number of factors
including new and aggressive immunosuppressive therapies, increased
survival in intensive care, increased numbers of transplant
procedures and the greater use of antibiotics worldwide.
[0004] In certain patient groups, fungal infection occurs at high
frequency; lung transplant recipients have a frequency of up to 20%
colonisation and infection with a fungal organism and fungal
infection in allogenic haemopoetic stem cell transplant recipients
is as high as 15% (Ribaud et al., 1999, Clin Infect Dis.
28:322-30).
[0005] Recently there has been increased awareness of the
contribution of fungal sensitisation, colonisation, allergy and
localised infection in the exacerbation of existing respiratory
diseases. Here fungi have been implicated in asthma, COPD,
brochiectasis and cystic fibrosis. Allergic bronchopulmonary
aspergillosis (ABPA) is a lower respiratory tract condition caused
by fungal colonisation, typically by Apsergillus fumigatus. ABPA
can be seen in asthmatics at a rate of 0.7-3.5% and cystic fibrosis
at a rate of 7-9%.
[0006] Currently there are four classes of antifungal drug are
available to treat systemic fungal infections. These are the
polyenes (e.g., amphotericin B), the azoles (e.g., ketoconazole or
itraconazole), the echinocandins (e.g., caspofungin) and
flucytosine.
[0007] The polyenes are the oldest class of antifungal agent being
first introduced in the 1950's. The exact mode of action remains
unclear but polyenes are only effective against organisms that
contain sterols in their outer membranes. It has been proposed that
amphotericin B interacts with membrane sterols to produce pores
allowing leakage of cytoplasmic components and subsequent cell
death.
[0008] Azoles work by inhibition of the 14.alpha.-demethylase via a
cytochrome P450-dependent mechanism. This leads to a depletion of
the membrane sterol ergosterol and the accumulation of sterol
precursors resulting in a plasma membrane with altered fluidity and
structure. Echinocandins work by the inhibition of the cell wall
synthetic enzyme .beta.-glucan synthase. This leads to abnormal
cell wall formation, osmotic sensitivity and cell lysis.
[0009] Flucytosine is a pyrimidine analogue interfering with
cellular pyrimidine metabolism as well DNA, RNA and protein
synthesis. However widespread resistance to flucyotosine limits its
therapeutic use.
[0010] It can be seen that to date the currently available
antifungal agents act primarily against only two cellular targets;
membrane sterols (polyenes and azoles) and .beta.-glucan synthase
(echinocandins).
[0011] Resistance to both azoles and polyenes has been widely
reported leaving only the recently introduced echinocandins to
combat invasive fungal infections. As the use of echinocandins
increases, resistance by fungi will inevitably occur.
[0012] The identification of new classes of antifungal agent is
required to give the promise of positive therapeutic outcomes to
patients.
[0013] Pyrrole compounds have also been identified as antifungal
agents. WO 2009/130481 discloses pyrrole compounds that may be used
in the prevention or treatment of fungal disease.
SUMMARY OF THE INVENTION
[0014] The present inventors have found that the pyrrole compound
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide (the compound of Formula I)
is a particularly effective antifungal agent. It shows high potency
in enzyme inhibition and fungal inhibition tests and has good
bioavailability and low toxicity. Tests have shown that this
pyrrole compound inhibits the growth of a wide variety of fungi, in
particular the human pathogenic fungi Aspergillus. This particular
compound has been shown to have activity against a wider spectrum
of species within the Aspergillus genus than other pyrrole
compounds. Further, the compound has been shown to exhibit
increased in vivo efficacy when compared to the known antifungal
drug Voriconazole, in particular improved efficacy against
Scedosporium fungi. The compound
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide may, therefore, be used to
effectively treat a wide variety of fungal infection and disease.
These results are described in the international patent application
having application number PCT/GB2015/053546, the entirety of which
is incorporated by reference herein.
[0015] The present inventors have recognised a need for effective
formulations of the pyrrole compound
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide. Formulations yielding high
bioavailability with minimal side-effects are required for the
compound to achieve optimal benefit in clinical use. There is
further a need for formulations of
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide which can be easily
administered to a patient in need thereof.
[0016] Accordingly, the present invention provides a pharmaceutical
composition suitable for oral administration wherein the
composition comprises spray-dried particles of a compound of
Formula I or a pharmaceutically acceptable salt thereof
##STR00001##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)
piperazin-1-yl)phenyl)-2-oxoacetamide
[0017] In one aspect, the composition suitable for oral
administration comprises spray-dried particles of the compound of
Formula I. In one aspect, the compound of Formula I is
substantially amorphous. In one aspect the pharmaceutical
composition further comprises one or more excipients. In one aspect
the composition comprises the excipient hydroxypropyl methyl
cellulose acetate succinate (HPMCAS). In one aspect, the mass ratio
of the compound of Formula I to excipient is from 1:100 to 1:1, for
example from 1:15 to 1:2. In one aspect, the pharmaceutical
composition comprises particles which are obtainable by
spray-drying from a solution comprising an organic solvent selected
from dichloromethane, methanol, and mixtures thereof. In one
aspect, the pharmaceutical composition is in the form of a solid
oral dosage form or a liquid oral dosage form. In one aspect, the
liquid oral dosage form further comprises a pharmaceutically
acceptable buffer having a pKa in the range 6.0 to 8.0. In one
aspect, the buffer is from 1 mM to 200 mM phosphate buffer wherein
the composition is buffered to about pH 7. In one aspect, the
pharmaceutical further comprises one or more pharmaceutically
acceptable binders and/or carriers and/or excipients and/or
diluents and/or adjuvants.
[0018] The present invention also provides a pharmaceutical
composition suitable for parenteral administration comprising (i) a
compound of Formula I or a pharmaceutically acceptable salt
thereof, (ii) a cyclodextrin or modified cyclodextrin, and (iii) a
polyethylene glycol.
[0019] In one aspect, the composition suitable for parenteral
administration comprises from 10 wt % to 40 wt % of a cyclodextrin
or modified cyclodextrin; and/or from 10 wt % to 40 wt % of a
polyethylene glycol. In one aspect, the cyclodextrin or modified
cyclodextrin is hydroxy propyl beta cyclodextrin. In one aspect,
the polyethylene glycol is PEG300 or PEG400. In one aspect, the
composition further comprises polyvinyl pyrrolidone (Povidone). In
one aspect, the compound of Formula I or the pharmaceutically
acceptable salt thereof is present at a concentration of from 1
mg/mL to 10 mg/mL. In one aspect, the composition further comprises
one or more pharmaceutically acceptable carriers and/or excipients
and/or diluents and/or adjuvants.
[0020] The present invention also provides a pharmaceutical
composition as described herein for use in a method of treatment of
a human or animal subject in need thereof, particularly in a method
of preventing or treating fungal infection in the subject.
Similarly, the present invention provides a method of preventing or
treating fungal infection in a human or animal subject in need
thereof, said method comprising administering to the human or
animal subject a therapeutically effective amount of a
pharmaceutical composition as described herein; and the use of a
pharmaceutical composition as described herein in the manufacture
of a medicament for use in the prevention or treatment of fungal
infection in a human or animal subject in need thereof.
[0021] The invention further provides a method of producing a
pharmaceutical composition comprising a compound of Formula I or a
pharmaceutically acceptable salt thereof, wherein said method
comprises spray-drying a solution of the compound of Formula (I) or
salt thereof. In one aspect, the method comprises: (i) dissolving
one or more excipients in a solvent; (ii) adding the compound of
Formula I to the solution produced in step (i); and (iii) spray
drying the solution produced in step (ii).
[0022] The invention further provides a pharmaceutical composition
suitable for oral administration wherein the composition comprises
substantially amorphous particles of a compound of Formula I or a
pharmaceutically acceptable salt thereof.
[0023] The compositions of the invention are beneficial as they
provide extremely high bioavailability of the compound of Formula I
and have minimal side-effects.
DESCRIPTION OF THE FIGURES
[0024] FIG. 1 shows pharmacokinetic data obtained in human trials
of a formulation of the compound of Formula I according to the
invention as described in Example 5. y-axis: Plasma C.sub.max
(.mu.g/mL); x-axis: time in hours.
[0025] FIG. 2 shows pharmacokinetic data obtained in human trials
of a formulation of the compound of Formula I according to the
invention as described in Example 5. y-axis: Plasma C.sub.max
(.mu.g/mL); x-axis: dose of the compound of Formula I (mg/kg).
[0026] FIG. 3 shows pharmacokinetic data obtained in human trials
of a formulation of the compound of Formula I according to the
invention as described in Example 5. y-axis: Plasma
AUC.sub.0-.infin. (.mu.gh/mL); x-axis: dose of the compound of
Formula I (mg/kg)
DETAILED DESCRIPTION OF THE INVENTION
[0027] As used herein, a pharmaceutically acceptable salt is a salt
with a pharmaceutically acceptable acid or base. Pharmaceutically
acceptable acids include both inorganic acids for example
hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic,
hydroiodic or nitric acid and organic acids for example citric,
fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic,
acetic, methanesulphonic, ethanesulphonic, benzenesulphonic,
p-toluenesulphonic acid, formic, acetic, propionic, glycolic,
lactic, pyruvic, oxalic, salicylic, trichloroacetic, picric,
trifluoroacetic, cinnamic, pamoic, malonic, mandelic, bismethylene
salicylic, ethanedisulfonic, gluconic, citraconic, aspartic,
stearic, palmitic, EDTA, p-aminobenzoic or glutamic acid, sulfates,
nitrates, phosphates, perchlorates, borates, acetates, benzoates,
hydroxynaphthoates, glycerophosphates or ketoglutarates. Further
examples of pharmaceutically acceptable inorganic or organic acid
addition salts include the pharmaceutically acceptable salts listed
in Journal of Pharmaceutical Science, 66, 2 (1977) which are known
to the skilled artisan. Pharmaceutically acceptable bases include
alkali metal (e.g. sodium or potassium) and alkali earth metal
(e.g. calcium or magnesium) hydroxides and organic bases for
example alkyl amines, aralkyl amines and heterocyclic amines,
lysine, guanidine, diethanolamine and choline. Also intended as
pharmaceutically acceptable acid addition salts are the hydrates
which the present compound is able to form. The acid addition salts
may be obtained as the direct products of compound synthesis. In
the alternative, the free base may be dissolved in a suitable
solvent containing the appropriate acid, and the salt isolated by
evaporating the solvent or otherwise separating the salt and
solvent. The compound of the active substance may form solvates
with standard low molecular weight solvents using methods known to
the skilled artisan.
[0028] Unless otherwise stated, all percentages mentioned herein
are weight percentages (wt %).
[0029] The invention provides a pharmaceutical composition suitable
for oral administration wherein the composition comprises
spray-dried particles of a compound of Formula I or a
pharmaceutically acceptable salt thereof.
##STR00002##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide
[0030] Preferably, the composition comprises spray-dried particles
of the compound of Formula I. Most preferably the composition
comprises the compound of Formula I in the form of the free
base.
[0031] Spray drying is a well-known technique used to produce
substantially amorphous particles of substances for example
pharmaceutically active substances e.g. drugs. Spray drying is
particularly beneficial for producing solid particles of
thermally-sensitive materials and has the advantage over other
drying techniques that a broadly consistent particle size is
obtained. Any suitable spray drying apparatus can be used to dry
the substance, and many spray-dryers are commercially available.
For example, the spray-dryer may be a single effect spray dryer or
a multiple effect spray dryer. Multiple effect spray dryers are
often preferred as they can be used to produce uniform particle
sizes. Spray drying is described in standard reference texts which
are readily available to the skilled person, for example A. S.
Mujumdar, Handbook of Industrial Drying, CRC Press 2014, which
describes spray-drying techniques and optimal choices thereof.
[0032] Preferably, the pharmaceutical composition suitable for oral
administration comprises a compound of Formula I which is
substantially amorphous. An amorphous particle is a particle which
lacks long-range crystallographic ordering. Preferably, the
compound of Formula 1 is more than 50% amorphous, for example more
than 70% amorphous, more preferably more than 90% amorphous, still
more preferably more than 95% amorphous, more preferably more than
99% amorphous, for example more than 99.5% amorphous or more than
99.9% amorphous. Substantially amorphous particles are therefore
particles in which the compound of Formula I has a low
crystallinity content, for example less than 50% crystallinity,
e.g. less than 30% crystallinity, preferably less than 10%,
especially less than 5% e.g. less than 1% crystallinity, for
example less than 0.5% or less than 0.1% crystallinity.
Crystallinity may be measured using methods familiar to those
skilled in the art. There are many methods of testing amorphous
particles which are known to the skilled person and which can be
used to determine whether a particle is amorphous or crystalline.
These methods include, but are not limited to powder X-ray
diffraction, differential scanning calorimetry, dynamic vapour
sorption, isothermal microcalorimetry, inverse gas chromatography,
near infra-red spectroscopy and solid-state NMR.
[0033] Preferably, the pharmaceutical composition suitable for oral
administration comprises particles of the compound of Formula I
which have an average particle size of from about 0.5 .mu.m to
about 1000 .mu.m, more preferably from about 1 .mu.m to about 500
.mu.m for example from 5 .mu.m to 100 .mu.m, for example from about
20 .mu.m to about 50 .mu.m. The term "average particle size" refers
to the value known as the D50. The term D50 means that 50 vol % of
the particles have a diameter that is smaller than this value, and
50 vol % of the particles have a diameter that is larger than this
value. The average particle size may be measured using standard
laser diffraction particle sizing techniques known in the art. One
example of an instrument to measure the particle size of the dry
powders is the Mastersizer 2000, manufactured by Malvern
Instruments Ltd (Worcestershire, UK).
[0034] Preferably, the pharmaceutical composition suitable for oral
administration comprises particles which are obtainable by
spray-drying from a solution comprising an organic solvent.
Preferably, the organic solvent is one or more solvents selected
from dicholoromethane, acetone, methanol and ethanol. More
preferably, the solvent is a mixture of two or more solvents
selected from dicholoromethane, acetone, methanol and ethanol.
Still more preferably, the solvent is a mixture of dichloromethane
and/or acetone with methanol and/or ethanol. Typically, the ratio
of dicholoromethane and/or acetone to methanol and/or ethanol is
from 1:1 to 5:1, for example from 2:1 to 4:1 e.g. 3:1. For example,
the solvent is often a mixture of dicholoromethane and methanol,
wherein the ratio of dicholoromethane to methanol is from 2:1 to
4:1 for example 3:1. Most preferably, the solvent is a 3:1 ratio of
dicholoromethane to methanol. Ratios of solvents can be determined
by mass or volume; volume ratios are preferred.
[0035] Preferably, the pharmaceutical composition suitable for oral
administration further comprises one or more excipients.
Pharmaceutically acceptable excipients known to the skilled person
include e.g. binding agents, for example syrup, acacia, gelatin,
sorbitol, tragacanth, polyvinylpyrrolidone (Povidone),
methylcellulose, ethylcellulose, sodium carboxymethylcellulose,
hydroxypropylmethylcellulose, sucrose and starch; fillers and
carriers, for example corn starch, gelatin, lactose, sucrose,
microcrystalline cellulose, kaolin, mannitol, dicalcium phosphate,
sodium chloride and alginic acid; and lubricants such as magnesium
stearate, sodium stearate and other metallic stearates, glycerol
stearate, stearic acid, silicone fluid, talc waxes, oils and
colloidal silica. Flavouring agents such as peppermint, oil of
wintergreen, cherry flavouring and the like can also be used. It
may be desirable to add a colouring agent to make the dosage form
readily identifiable. Tablets may also be coated by methods well
known in the art.
[0036] More preferably, the pharmaceutical composition suitable for
oral administration comprises an excipient selected from (i) a
cellulose or modified cellulose for example hypromellose,
hydroxypropyl cellulose, hydroxyl propyl methyl cellulose (HPMC),
hydroxyl propyl methyl cellulose acetate (HPMCA) and hydroxy propyl
methyl cellulose acetate succinate (HPMCAS) and (ii) a
vinylpyrrolidone-vinyl acetate copolymer having a mass ratio of
vinylpyrrolidone to vinyl acetate in the copolymer of from 10:1 to
1:10, for example from 5:1 to 1:5 e.g. 3:1 to 1:1, for example from
2:1 to 1:1, e.g. 3:2 (which can also be expressed as 6:4), for
example Kollidon VA64 or Kollidon VA64 Fine, both available from
BASF; Kollidon VA64 is preferred. The pharmaceutical composition
may comprise a mixture of (i) and (ii). More preferably, the
pharmaceutical composition suitable for oral administration
comprises a cellulose-based excipient according to option (i). Most
preferable excipients include HPMC, HPMCA and HPMCAS; HPMCAS is
still more preferred.
[0037] HPMCAS is hydroxypropyl methyl cellulose acetate succinate.
The content of acetyl and succinoyl groups in the polymer can
determine the properties of the HPMCAS. Type L HPMCAS represents
polymers with high ratio of succinoyl substitution to acetyl
substitution; typically 14-18 wt % succinoyl content and 5-9 wt %
acetyl content. Type M HPMCAS represents polymers having a lower
ratio; typically 10-14 wt % succinoyl content and 7-11 wt % acetyl
content. Type H HPMCAS typically comprises 4-8 wt % HPMCAS
succinoyl content and 10-14 wt % acetyl content. Type L HPMCAS
usually dissolves at around pH.gtoreq.5.5; type M HPMCAS typically
dissolves around pH.gtoreq.6.0 and type H HPMCAS typically
dissolves around pH.gtoreq.6.8. Usually, the HPMCAS comprises from
12-28 wt % methoxyl and from 4-28% hydroxypropoxy. HPMCAS is
readily available commercially from suppliers such as Shin-Etsu
(product AQOAT) and from Ashland ("AquaSolve"). Any suitable HPMCAS
known to those skilled in the art can be used.
[0038] Preferably, when an excipient is present in the
pharmaceutical composition suitable for oral administration, the
mass ratio of the compound of Formula I to the excipient is from
1:100 to 1:1. More preferably, the mass ratio of the compound of
Formula 1 to the excipient is from 1:50 to 1:1, for example from
1:25 to 1:1.5 e.g. from 1:15 to 1:2, for example 1:10, 1:7, 1:5,
1:4 or 1:3. Most preferably the mass ratio of the compound of
Formula 1 to the excipient is from 1:9 to 1:11, for example 1:10,
or is from 1:3 to 1:5, for example 1:4. A mass ratio of the
compound of Formula 1 to the excipient of 1:4 can be achieved by,
for example, a mass ratio of the compound of Formula 1 to the
excipient of 4:16.
[0039] The pharmaceutical composition of the invention suitable for
oral administration typically contains from 1 to 50 wt % of the
compound of Formula I; more typically from 4 to 40 wt % for example
from 7 to 30 wt %. For example, the pharmaceutical composition may
comprise from 5 to 20 wt %, for example from 8 to 15 wt %, e.g.
from 9 to 11 wt % e.g. 10 wt %. A composition comprising about 10
wt % of the compound of Formula I can, for example, be produced
using a composition comprising only the compound of Formula I and
an excipient for example HPMCAS by using a weight ratio of 1:9
(compound of Formula I:HPMCAS). Alternatively, the pharmaceutical
composition may comprise from 10 to 40 wt % of the compound of
Formula I, for example from 15 to 30 wt % e.g. from 18 to 22 wt %
for example about 20 wt %. A composition comprising 20 wt % of the
compound of Formula I can, for example, be produced using a
composition comprising only the compound of Formula I and an
excipient for example HPMCAS by using a weight ratio of 4:16
(compound of Formula I:HPMCAS).
[0040] The pharmaceutical composition suitable for oral
administration may further comprise one or more pharmaceutically
acceptable binders and/or carriers and/or excipients (i.e. further
to excipient(s) above) and/or diluents and/or adjuvants.
[0041] The pharmaceutical composition suitable for oral
administration may preferably be presented as: discrete units such
as capsules, sachets or tablets each containing a predetermined
amount of the active agent; as a powder or granules; as a solution
or a suspension of the active agent in an aqueous liquid or a
non-aqueous liquid; or as an oil-in-water liquid emulsion or a
water in oil liquid emulsion; or as a bolus etc. Preferably, the
pharmaceutical composition suitable for oral administration is in
the form of (i) a solid oral dosage form or (ii) a liquid oral
dosage form. More preferably, the pharmaceutical composition
suitable for oral administration is in the form of a solid oral
dosage form.
[0042] Solid oral dosage forms include, for example, tablets and
capsules. Solid oral forms may contain, together with the active
compound, solubilising agents, e.g. cyclodextrins or modified
cyclodextrins; diluents, e.g. lactose, dextrose, saccharose,
cellulose, corn starch or potato starch; lubricants, e.g. silica,
talc, stearic acid, magnesium or calcium stearate, and/or
polyethylene glycols; binding agents; e.g. starches, arabic gums,
gelatin, methylcellulose, carboxymethylcellulose or polyvinyl
pyrrolidone; disaggregating agents, e.g. starch, alginic acid,
alginates or sodium starch glycolate; effervescing mixtures;
dyestuffs; sweeteners; wetting agents, e.g. lecithin, polysorbates,
laurylsulphates; and, in general, non-toxic and pharmacologically
inactive substances used in pharmaceutical formulations. Such
pharmaceutical preparations may be manufactured in any known
manner, for example, by means of mixing, granulating, tabletting,
sugar-coating, or film coating processes.
[0043] A tablet may be made by compression or moulding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared by compressing in a suitable machine the active agent in a
free flowing form such as a powder or granules, optionally mixed
with a binder, lubricant, inert diluent, preservative,
surface-active or dispersing agent. Moulded tablets may be made by
moulding in a suitable machine a mixture of the powdered compound
moistened with an inert liquid diluent. The tablets may optionally
be coated or scored and may be formulated so as to provide slow or
controlled release of the active agent.
[0044] Other solid oral dosage forms include lozenges comprising
the active agent in a flavoured base, usually sucrose and acacia or
tragacanth and pastilles comprising the active agent in an inert
base such as gelatin and glycerin, or sucrose and acacia.
[0045] Liquid oral dosage forms include solutions, syrups,
emulsions and suspensions. The solutions may contain solubilising
agents e.g. cyclodextrins or modified cyclodextrins. The syrups may
contain as carriers, for example, saccharose or saccharose with
glycerine and/or mannitol and/or sorbitol. Liquid oral dosage forms
include mouthwashes comprising the active agent in a suitable
liquid carrier.
[0046] Preferably, when the pharmaceutical composition suitable for
oral administration is in the form of a liquid oral dosage form,
the liquid oral dosage form further comprises a pharmaceutically
acceptable buffer having a pKa in the range 6.0 to 8.0, preferably
around pH 7, for example from pH 6.5 to pH 7.5 e.g. from pH 7.0 to
pH 7.5, preferably around pH 7.1 to pH 7.3 e.g. around pH 7.2. Any
pharmaceutically acceptable buffer which is capable of maintaining
the pH of the solution in this range can be used. For example,
suitable buffer salts include citrate (e.g. sodium citrate/citric
acid), phosphate (e.g. Na.sub.2HPO.sub.4/NaH.sub.2PO.sub.4) and
carbonate (e.g. sodium carbonate/sodium bicarbonate). Phosphate
buffer is preferred. The salt concentration of the buffer can be
any suitable salt concentration to produce a desired liquid oral
formulation. Generally, the salt concentration in the buffer
solution is chosen to maintain the pH of the solution at the
desired value, for example at around pH 7 (e.g. pH 7.2). Typical
salt concentrations are from 1 mM to 200 mM, for example from 5 mM
to 100 mM e.g. from 10 mM to 50 mM, for example from 20 mM to 40
mM, e.g. around 25 mM, around 30 mM, or around 35 mM.
[0047] Preferred compositions of the invention suitable for oral
administration therefore comprise spray-dried particles of a
compound of Formula I or a pharmaceutically acceptable salt
thereof, wherein the compound of Formula I is substantially
amorphous and wherein the composition further comprises one or more
excipients.
[0048] More preferred compositions of the invention suitable for
oral administration comprise spray-dried particles of a compound of
Formula I, wherein the compound of Formula I is substantially
amorphous and wherein the composition further comprises the
excipient hydroxypropyl methyl cellulose acetate succinate
(HPMCAS).
[0049] Still more preferred compositions of the invention suitable
for oral administration comprise spray-dried particles of the
compound of Formula I, wherein the compound of Formula I is
substantially amorphous and wherein the composition further
comprises the excipient HPMCAS, and wherein the mass ratio of the
compound of Formula I to the excipient is from 1:100 to 1:1,
preferably from 1:15 to 1:2.
[0050] Yet more preferred compositions of the invention suitable
for oral administration comprise spray-dried particles of the
compound of Formula I, wherein the compound of Formula I is
substantially amorphous and is obtainable by spray-drying from a
solution comprising an organic solvent selected from
dichloromethane, methanol, and mixtures thereof, and wherein the
composition further comprises the excipient HPMCAS, and wherein the
mass ratio of the compound of Formula I to the excipient is from
1:15 to 1:2.
[0051] Most preferred compositions of the invention suitable for
oral administration comprise spray-dried particles of the compound
of Formula I, wherein the compound of Formula I is substantially
amorphous, and wherein the composition comprises 10 wt % of the
compound of Formula I and 90 wt % HPMCAS (i.e. the mass ratio of
the compound of Formula I to HPMCAS is 1:9). The compound of
formula I is most preferably obtainable by spray-drying from a 3:1
v/v mixture of dichloromethane:methanol.
[0052] Similarly, most preferred compositions of the invention
suitable for oral administration comprise spray-dried particles of
the compound of Formula I, wherein the compound of Formula I is
substantially amorphous, and wherein the composition comprises 20
wt % of the compound of Formula I and 80 wt % HPMCAS (i.e. the mass
ratio of the compound of Formula I to HPMCAS is 1:4). The compound
of formula I is most preferably obtainable by spray-drying from a
3:1 v/v mixture of dichloromethane:methanol.
[0053] The invention also provides a pharmaceutical composition
suitable for oral administration wherein the composition comprises
substantially amorphous particles of a compound of Formula I or a
pharmaceutically acceptable salt thereof. The composition is as
described herein.
[0054] More preferably, the invention provides a pharmaceutical
composition suitable for oral administration comprising the
compound of Formula I wherein the compound of Formula I is
substantially amorphous and the composition further comprises
HPMCAS, wherein the mass ratio of the compound of Formula I to the
HPMCAS is from about 1:3 to 1:5, for example 1:4, or from about 1:8
to 1:10, for example about 1:9. Therefore, the invention provides a
pharmaceutical composition suitable for oral administration
comprising the compound of Formula I and HPMCAS, wherein the
compound of Formula I is substantially amorphous and the
composition comprises 10 wt % of the compound of Formula I and 90
wt % HPMCAS. The invention also provides a pharmaceutical
composition suitable for oral administration comprising the
compound of Formula I and HPMCAS, wherein the compound of Formula I
is substantially amorphous and the composition comprises 20 wt % of
the compound of Formula I and 80 wt % HPMCAS.
[0055] The invention also provides a method of producing a
pharmaceutical composition comprising a compound of Formula I or a
pharmaceutically acceptable salt thereof
##STR00003##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide
[0056] wherein said method comprises spray-drying a solution of the
compound of Formula (I) or salt thereof.
[0057] Any suitable spray-drying technique can be used.
Spray-drying is described above.
[0058] Preferably, the method of producing a pharmaceutical
composition suitable for oral administration comprises the steps
of:
[0059] i) dissolving one or more excipients in a solvent;
[0060] ii) adding the compound of Formula I to the solution
produced in step (i); and
[0061] iii) spray drying the solution produced in step (ii).
[0062] Preferably, one or more of the one or more excipients is an
excipient described herein. More preferably, the one or more
excipients is (i) a cellulose or modified cellulose as described
herein or (ii) a vinylpyrrolidone-vinyl acetate copolymer as
described herein, or a mixture of (i) and (ii). Most preferably,
the excipient is HPMCAS as described herein.
[0063] Preferably, the solvent is an organic solvent as described
herein. More preferably, the solvent is a mixture of
dichloromethane and/or acetone with methanol and/or ethanol. Still
more preferably, the solvent is a mixture of dicholoromethane and
methanol, wherein the ratio of dicholoromethane to methanol is from
2:1 to 4:1 for example 3:1. Most preferably, the solvent is a 3:1
ratio of dicholoromethane to methanol.
[0064] For example, the invention therefore provides a method of
producing a pharmaceutical composition suitable for oral
administration as described herein wherein: [0065] the excipient is
hydroxypropyl methyl cellulose acetate succinate (HPMCAS); [0066]
the solvent is a mixture of dichloromethane and methanol, wherein
the volume ratio of dichloromethane to methanol is from 5:1 to 1:1;
[0067] the concentration of the excipient in the solvent is from 5%
to 20% w/v; and [0068] the compound of Formula I is added to the
solution of the excipient in the solvent to give a concentration of
0.5% to 10% by mass. More preferably, the invention provides a
method of producing a pharmaceutical composition suitable for oral
administration as described herein wherein: [0069] the excipient is
hydroxypropyl methyl cellulose acetate succinate (HPMCAS); [0070]
the solvent is a mixture of dichloromethane and methanol, wherein
the volume ratio of dichloromethane to methanol is from 4:1 to 2:1;
[0071] the concentration of the excipient in the solvent is from 7%
to 18% w/v; and [0072] the compound of Formula I is added to the
solution of the excipient in the solvent to give a concentration of
0.5% to 6% by mass. Still more preferably, the invention provides a
method of producing a pharmaceutical composition suitable for oral
administration as described herein wherein: [0073] the excipient is
hydroxypropyl methyl cellulose acetate succinate (HPMCAS); [0074]
the solvent is a mixture of dichloromethane and methanol, wherein
the volume ratio of dichloromethane to methanol is about 3:1; and
[0075] (i) the concentration of the excipient in the solvent is
from about 7 wt % to about 11 wt %; and the compound of Formula I
is added to the solution of the excipient in the solvent to give a
concentration of about 0.5% to about 2% by mass; or [0076] (ii) the
concentration of the excipient in the solvent is from about 12% to
about 18%; and the compound of Formula I is added to the solution
of the excipient in the solvent to give a concentration of about 3%
to about 5% by mass Most preferably, the invention provides a
method of pharmaceutical composition suitable for oral
administration comprising [0077] i) dissolving from about 7 wt % to
about 11 wt % (e.g. about 9 wt %) of HPMCAS in a solvent wherein
the solvent is a 3:1 v/v mixture of dichloromethane:methanol;
[0078] ii) adding the compound of Formula I to the solution
produced in step (i) to yield a solution wherein the concentration
of the compound of Formula I is about 0.5% to about 2% by mass
(e.g. about 1% by mass); and [0079] iii) spray drying the solution
produced in step (ii). Similarly, the invention provides a method
of pharmaceutical composition suitable for oral administration
comprising [0080] i) dissolving from about 12 wt % to about 18 wt %
(e.g. about 16 wt %) of HPMCAS in a solvent wherein the solvent is
a 3:1 v/v mixture of dichloromethane:methanol; [0081] ii) adding
the compound of Formula I to the solution produced in step (i) to
yield a solution wherein the concentration of the compound of
Formula I is about 3% to about 5% by mass (e.g. about 4% by mass);
and [0082] iii) spray drying the solution produced in step
(ii).
[0083] The invention also provides a pharmaceutical composition
suitable for parenteral administration comprising (i) a compound of
Formula I or a pharmaceutically acceptable salt thereof,
##STR00004##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide
[0084] (ii) cyclodextrin or modified cyclodextrin, and (iii)
polyethylene glycol.
[0085] Pharmaceutically acceptable salts are described herein.
Preferably, the pharmaceutical composition suitable for parenteral
administration comprises a compound of Formula I. More preferably,
the pharmaceutical composition suitable for parenteral
administration comprises a compound of Formula I in the form of the
free base.
[0086] Preferably, cyclodextrin is present in an amount of from 10
wt % to 40 wt % with reference to the pharmaceutical composition.
Typical amounts of cyclodextrin present in the composition are from
20 wt % to 30 wt % for example about 25 wt %.
[0087] Preferably, polyethylene glycol is present in an amount of
from 10 wt % to 40 wt % with reference to the pharmaceutical
composition. Typical amounts of polyethylene glycol present in the
composition are from 20 wt % to 30 wt % for example about 25 wt
%.
[0088] The pharmaceutical composition suitable for parenteral
administration may comprise any suitable cyclodextrin or mixture
thereof. Typical cyclodextrins contain a number of glucose monomers
ranging from six to eight units in a ring, creating a cone shape.
Cyclodextrins are often denoted as a (alpha)-cyclodextrin
(comprising a 6-membered sugar ring molecule); 13
(beta)-cyclodextrin (comprising a 7-membered sugar ring molecule)
or y (gamma)-cyclodextrin (comprising an 8-membered sugar ring
molecule). Because cyclodextrins are hydrophobic inside and
hydrophilic outside, they can form complexes with hydrophobic
compounds. Thus they can enhance the solubility and bioavailability
of such compounds. Alpha-, beta-, and gamma-cyclodextrin are all
generally recognized as safe by the FDA. Cyclodextrins (CDs) can be
modified in various ways whilst still be suitable for use in the
compositions of the invention. For example, known modified
cyclodextrins include Hydroxyethyl-.beta.-CD (HE-.beta.-CD),
Hydroxypropyl-.beta.-CD (HP-.beta.-CD), Sulfobutylether-.beta.-CD
(SBE-.beta.-CD), Methyl-.beta.-CD (M-.beta.-CD), Dimethyl-.beta.-CD
(DM-.beta.-CD/DIMEB), Randomly dimethylated-.beta.-CD
(RDM-.beta.-CD), Randomly methylated-.beta.-CD
(RM-.beta.-CD/RAMEB), Carboxymethyl-.beta.-CD (CM-.beta.-CD),
Carboxymethyl ethyl-.beta.-CD (CME-.beta.-CD), Diethyl-.beta.-CD
(DE-.beta.-CD), Tri-O-methyl-.beta.-CD (TRIMER),
Tri-O-ethyl-.beta.-CD (TE-.beta.-CD), Tri-O-butyryl-.beta.-CD
(TB-.beta.-CD), Tri-O-valeryl-.beta.-CD (TV-.beta.-CD),
Di-O-hexanoyl-.beta.-CD (DH-.beta.-CD), Glucosyl-.beta.-CD
G1-.beta.-CD Maltosyl-.beta.-CD (G2-.beta.-CD), and
2-hydroxy-3-trimethyl-ammoniopropyl-.beta.-CD (HTMAPCD).
Cyclodextrins and their uses in pharmaceutical formulations are
disclosed in standard reference texts, for example Fromming and
Szejtli, Cyclodextrins in Pharmacy, Springer, 1993, which describes
the advantages of specific cyclodextrins in pharmaceutical
formulations.
[0089] Preferably, the cyclodextrin is selected from hydroxy propyl
beta cyclodextrin and sulfobutyl ether beta-cyclodextrin (Captisol)
and mixtures thereof. Hydroxy propyl beta cyclodextrin is
preferred.
[0090] The pharmaceutical composition suitable for parenteral
administration may comprise any suitable polyethylene glycol or
mixture thereof. For example, the composition may comprise any
polyethylene glycol approved for intraveneous use. Polyethylene
glycols which can be used include PEG200-PEG500, for example PEG300
and/or PEG400. PEG 300 and PEG 400 are preferred, and PEG400 is
most preferred.
[0091] As the skilled person will appreciate, the number following
the term "PEG" (e.g. 300 in "PEG300") refers to the average
molecular weights of the PEG molecule. PEG400 thus typically
comprises approximately 9 ethylene glycol units in each polymer
molecule, and PEG 300 typically comprises 7 ethylene glycol units
in each polymer molecule. However, as the skilled person will
appreciate, many commercially available PEGs are polydisperse. In
general terms, the molecular weight distribution can be
characterized statistically in terms of its weight average
molecular weight (Mw) and its number average molecular weight (Mn),
the ratio of which is often referred to as the polydispersity index
(Mw/Mn). Both Mw and Mn can be measured by conventional techniques,
for example, by mass spectrometry.
[0092] Preferably, the pharmaceutical composition suitable for
parenteral administration comprises one or more dispersing agents
for example low molecular weight povidone (polyvinyl pyrrolidone).
Preferably, the povidone is endotoxin-free. Povidones are available
from commercial suppliers for example Ashland (Plasdone).
Preferably the povidone has a K-value of from 5 to 20 for example
from 10 to 18. For example, the Povidone may have a nominal
molecular weight of about 4000 and a K value of from about 10 to
about 14. Alternatively the povidone may have a nominal molecular
weight of about 10000 and a K value of from about 15 to about 18.
The K value is a function of the average degree of polymerisation
and the intrinsic viscosity of the polymer and can be calculated
from the kinematic viscositiy of an aqueous solution of the
polymer. Preferably, the povidone has a T.sub.g (glass transition
temperature) of from about 110.degree. C. to about 130.degree. C.
e.g. from about 120.degree. C. to about 126.degree. C. The
pharmaceutical composition may comprise a mixture of two or more
povidones.
[0093] Preferably, when the pharmaceutical composition suitable for
parenteral administration comprises a povidone or mixture thereof,
the povidone or mixture thereof is present in an amount of from 0.1
to 5 wt %, more preferably from 0.5 to 2 wt %, still more
preferably about 1 wt % relative to the total mass of the
composition.
[0094] Preferably, the compound of Formula I is present in the
pharmaceutical composition suitable for parenteral administration
at a concentration of from 1 mg/mL to 10 mg/mL. More preferably the
concentration of the compound of Formula I in the pharmaceutical
composition suitable for parenteral administration is from 2 to 7
mg/mL for example from 3 to 5 mg/mL e.g. 4 mg/mL.
[0095] The pharmaceutical composition suitable for parenteral
administration may further comprise one or more pharmaceutically
acceptable carriers and/or excipients and/or diluents and/or
adjuvants. For example, the composition may contain as carrier, for
example, sterile water, or may be in the form of a sterile,
aqueous, isotonic saline solutions.
[0096] Preferably, the pharmaceutical composition suitable for
parenteral administration is adjusted to a final pH of from about
pH 4 to about pH 8.
[0097] More preferably, the pharmaceutical composition suitable for
parenteral administration is adjusted to a final pH of from about
pH 4 to about pH 6, for example from about pH 4.5 to about pH 5.5,
e.g. about pH 5, for example pH 5.0. The pH of the pharmaceutical
composition may be adjusted using any pharmaceutically acceptable
acid or base. Phosphoric acid is preferred.
[0098] Preferred pharmaceutical compositions are sterile and
pyrogen free.
[0099] Preferred compositions of the invention suitable for
parenteral administration therefore comprise: [0100] from 10 wt %
to 40 wt % cyclodextrin or modified cyclodextrin; [0101] from 10 wt
% to 40 wt % polyethylene glycol; and [0102] a dispersing agent for
example povidone.
[0103] For example, compositions of the invention suitable for
parenteral administration may comprise: [0104] from 1 to 10 mg/mL
of the compound of Formula I or a pharmaceutically acceptable salt
thereof; [0105] from 10 wt % to 40 wt % hydroxyl propyl beta
cyclodextrin; [0106] from 10 wt % to 40 wt % PEG300 or PEG400; and
[0107] a dispersing agent for example povidone, wherein the
povidone is as described herein; and wherein the pH of the
composition is adjusted to from about pH 4 to about pH 8.
[0108] More preferred compositions of the invention suitable for
parenteral administration comprise: [0109] from 1 to 10 mg/mL of
the compound of Formula I or a pharmaceutically acceptable salt
thereof; [0110] from 10 wt % to 40 wt % hydroxyl propyl beta
cyclodextrin; [0111] from 10 wt % to 40 wt % PEG300 or PEG400; and
[0112] a dispersing agent for example povidone, wherein the
povidone is as described herein; and wherein the pH of the
composition is adjusted to from about pH 4 to about pH 6.
[0113] Still more preferred compositions of the invention suitable
for parenteral administration comprise: [0114] from 3 to 5 mg/mL of
the compound of Formula I; [0115] from 20 wt % to 30 wt % hydroxyl
propyl beta cyclodextrin; [0116] from 20 wt % to 30 wt % PEG300 or
PEG400, preferably PEG400; and [0117] from 0.1 to 5 wt % povidone;
and wherein the pH of the composition is adjusted to from about pH
4.5 to about pH 5.5.
[0118] Most preferred compositions of the invention suitable for
parenteral administration comprise: [0119] 4 mg/mL (relative to the
final volume of the composition) of the compound of Formula I
[0120] wt % hydroxy propyl beta cyclodextrin; [0121] wt % PEG400;
[0122] 1 wt % polyvinyl pyrrolidone (Povidone); [0123] phosphoric
acid in sufficient amount to adjust the pH of the pharmaceutical
composition to pH 5.0; and [0124] water to 100%.
[0125] As described herein, a pharmaceutical composition of the
invention can further comprise one or more adjuvants for example a
local anaesthetic, preservative or buffering agent.
[0126] Pharmaceutically acceptable binders include solution binders
and dry binders. Solution binders are dissolved in a solvent (for
example water or alcohol can be used in wet granulation processes).
Examples include gelatin, cellulose, cellulose derivatives,
polyvinylpyrrolidone, starch, sucrose and polyethylene glycol. Dry
binders are added to the powder blend, either after a wet
granulation step, or as part of a direct powder compression (DC)
formula. Examples include cellulose, methyl cellulose,
polyvinylpyrrolidone and polyethylene glycol.
[0127] Pharmaceutical carriers include liposomes, nanospheres,
micelles, protein-DNA complexes, nanogels and natural solvents for
example aqueous and non-aqueous solutions.
[0128] Other substances useful as excipients, diluents or carriers
include acacia, alginate, alginic acid, aluminum acetate, benzyl
alcohol, butyl paraben, butylated hydroxy toluene, citric acid,
calcium carbonate, candelilla wax, croscarmellose sodium,
confectioner's sugar, colloidal silicone dioxide, cellulose,
calcium phosphate, carnuba wax, corn starch, carboxymethylcellulose
calcium, calcium stearate, calcium disodium EDTA, copolyvidone,
hydrogenated castor oil, calcium hydrogen phosphate dehydrate,
cetylpyridine chloride, cysteine HCl, crosspovidone, disodium
hydrogen phosphate, dimethicone, sodium erythrosine, ethyl
cellulose, gelatin, glyceryl monooleate, glycerine, glycine,
glyceryl monostearate, glyceryl behenate, hydroxy propyl cellulose,
hydroxyl propyl methyl cellulose, hypromellose, HPMC pthalate,
lactose, magnesium stearate, mannitol, methyl cellulose, magnesium
carbonate, mineral oil, magnesium oxide, methyl paraben, povidone,
polysorbate 80, polyethylene oxide, polaxamer 407 or 188, potassium
bicarbonate, potassium sorbate, potato starch, phosphoric acid,
polyoxy stearate, sodium starch glycolate, sodium crossmellose,
sodium lauryl sulphate, starch, silicon dioxide, sodium benzoate,
stearic acid, sucrose, sorbic acid, sodium carbonate, saccharin
sodium, sodium alginate, silica gel, sorbiton monooleate, sodium
stearyl fumarate, sodium chloride, sodium metabisulfite, sodium
citrate dehydrate, sodium carboxy methyl cellulose, succinic acid,
sodium propionate, titanium dioxide, talc, triacetin and triethyl
citrate.
[0129] A pharmaceutical composition as described herein may
comprise particles of the compound of Formula I wherein the average
particle size (as described herein) has undergone particle size
reduction by micronisation or nanonisation technologies.
[0130] The compositions of the invention are particularly
advantageous as they provide the compound of Formula I with
increased bioavailability. As used herein, bioavailability is
defined such that a drug for example the compound of Formula I,
when administered intraveneously, has a bioavailability of 100%.
The pharmaceutical compositions of the invention which are suitable
for oral administration are particularly beneficial as they can
provide the compound of Formula I with high bioavailability.
Preferably, the composition of the invention provides the compound
of Formula I with a bioavailability of at least 50%, more
preferably at least 70% for example at least 80%, still more
preferably at least 90% for example at least 95%. As the skilled
person will appreciate, bioavailability can be determined by
numerous factors including the nature of the subject to which the
composition is administered (age, weight, sex etc). Therefore, a
negative result in one subject group is not determinative.
[0131] Bioavailability can be determined by pharmacokinetic (PK)
studies in which plasma drug concentration is determined as a
funcation of time after both intravenous (IV) and extravascular
(e.g., oral) administration. The absolute bioavailability
(F.sub.abs) is the dose (D)-corrected area under curve (AUC)
(non-intravenous) divided by AUC (intravenous). As used herein,
F.sub.abs for a drug administered by the oral route (PO) is
calculated using:
F abs = 1 0 0 AUC PO D IV AUC IV D PO ##EQU00001##
[0132] The compositions of the invention are useful in treating
medical conditions in a human or animal subject in need
thereof.
[0133] Accordingly, the invention provides a pharmaceutical
composition as described herein for use in a method of treatment of
a human or animal subject in need thereof. Preferably, the
invention provides a pharmaceutical composition as described herein
for use in the treatment of a human or animal subject in need
thereof, wherein the treatment comprises prevention of or treatment
of fungal infection in the subject.
[0134] The invention also provides a method of preventing or
treating fungal infection in a human or animal subject in need
thereof, said method comprising administering to the human or
animal subject a therapeutically effective amount of a
pharmaceutical composition as described herein.
[0135] The invention also provides the use of a pharmaceutical
composition as described herein in the manufacture of a medicament
for use in the prevention or treatment of fungal infection in a
human or animal subject in need thereof. A pharmaceutical
composition of the invention may be used in a method of treating a
human or animal subject wherein the treatment comprises
administration of the composition in combination with a further
antifungal agent as described herein.
[0136] A therapeutically effective amount of a composition of the
invention may be administered to a patient in need thereof. For
example, the composition is typically administered in an amount
such as to provide to the subject a daily dose of the compound of
Formula I of up to 200 mg, e.g. up to 100 mg or up to 50 mg per kg
of body weight, for example from 0.001 to 200 or 0.001 to 50 mg per
kg of body weight, according to (for example) the age, weight and
conditions of the subject to be treated, the type and severity of
the disease and the frequency and route of administration.
Preferably, daily dosage levels are up to 200 mg, e.g. up to 150
mg, up to 100 mg, up to 50 mg or up to 40 mg per kg of body weight.
Daily dosage levels are for example at least 1 mg, at least 2 mg or
at least 5 mg per kg of body weight. In one embodiment the daily
dosage level is from 0.05 mg to 2 g, preferably from 0.1 mg to 10
mg. The appropriate dosage level can be readily determined by the
skilled physician.
[0137] Where a composition of the invention is administered
together with a second antifungal agent, the second antifungal
agent is typically administered at or below the standard dose used
for that drug. In this manner, known antifungal agents may be
administered in lower doses than are currently used, resulting in a
reduction in toxic effects.
[0138] The composition of the invention is useful in the treatment
of or prevention of fungal disease. Preferably, the fungal disease
comprises an infection by a fungus, for example an Ascomycete.
Preferably, the fungal disease comprises an infection by an
organism selected from the genera Absidia; Acremonium; Alternaria;
Aspergillus; Bipolaris; Blastomyces; Blumeria; Cladosporium;
Coccidioides; Colletotrichium; Curvularia; Encephalitozoon;
Epicoccum; Epidermophyton; Exophiala; Exserohilum; Fusarium;
Histoplasma; Leptosphaeria; Microsporum; Mycosphaerella;
Neurospora, Paecilomyces; Penicillium; Phytophthora; Plasmopara;
Pneumocystis; Pyricularia; Pythium; Puccinia; Rhizoctonia;
Rhizomucor; Scedosporium; Scopulariopsis; Trichophyton;
Trichosporon; and Ustilago.
[0139] Preferably, the fungal disease comprises an infection by an
organism of the genus Aspergillus, Scedosporium or Fusarium, for
instance, the fungal disease comprises an infection by an organism
of the genus Aspergillus or Scedosporium, in particular
Aspergillus. In one embodiment, the fungal disease comprises an
infection by an organism of the genus Aspergillus. In another
embodiment, the fungal disease comprises an infection by an
organism of the genus Scedosporium.
[0140] Preferably, the fungal disease comprises an infection by an
organism selected from the species Absidia corymbifera; Acremonium
spp; Alternaria alternata; Aspergillus flavus; Aspergillus
fumigatus; Aspergillus nidulans; Aspergillus niger; Aspergillus
parasiticus; Aspergillus terreus; Bipolaris spp; Blastomyces
dermatitides; Blumeria graminis; Cladosporium cladosporoides;
Cladosporium herbarium; Coccidioides immitis; Coccidioides
posadasii; Curvularia lunata; Colletotrichium trifolii;
Encephalitozoon cuniculi; Epicoccum nigrum; Epidermophyton
floccosum; Exophiala spp; Exserohilum rostratum; Fusarium
graminarium; Fusarium solani; Fusarium sporotrichoides; Histoplasma
capsulatum; Leptosphaeria nodorum; Microsporum canis;
Mycosphaerella graminicola; Paecilomyces lilanicus; Paecilomyces
varioti; Penicillium chrysogenum; Phytophthora capsici;
Phytophthora infestans; Plasmopara viticola; Pneumocystis jiroveci;
Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium
ultimum; Rhizoctonia solani; Rhizomucor spp; Rhizopus spp;
Scedosporium apiospermum; Scedosporium prolificans; Scedosporium
species d; Scopulariopsis brevicaulis; Trichophyton mentagrophytes;
Trichophyton interdigitale; Trichophyton rubrum; Trichosporon
asahii; Trichosporon beigelii; and Ustilago maydis.
[0141] Preferably, the fungal disease comprises an infection by A.
fumigatus, A. flavus, A. terreus, A. niger, A. lentulus, S.
apiospermum, S. prolificans, or S. species d. Particularly, the
fungal disease comprises an infection by A. fumigatus, A. flavus,
A. terreus or A. niger. In one embodiment, the fungal disease
comprises an infection by S. prolificans.
[0142] Examples of fungal diseases which can be prevented or
treated using a composition of the invention include both systemic
and superficial infections. The fungal diseases include invasive
fungal diseases caused by Aspergillus species for example
aspergillosis, but also local forms of these infections. For
instance, the fungal diseases include invasive fungal diseases
caused by Aspergillus species for example aspergillosis, but also
local forms of these infections. Compositions of the invention is
particularly useful against diseases caused by Aspergillus species,
for which a fungicidal drug is required which has lower toxicity
than amphotericin. The invention also provides for the treatment of
dermatological infections.
[0143] The pharmaceutical composition of the invention is, in one
embodiment, for use in the prevention or treatment of a disease
caused by Aspergillus species. The diseases caused by Aspergillus
species include diseases caused by A. fumigatus, A. flavus, A.
terreus and A. niger.
[0144] Examples of systemic infections which might be prevented or
treated using a pharmaceutical composition of the invention
include: pulmonary aspergillosis, e.g. in immunosuppressed patients
for example bone marrow recipients or AIDS patients; systemic
aspergillosis; rhinocerebral mucomycosis; blastomycosis;
histoplasmosis; coccidiomycosis; paracoccidiomycosis; lobomycosis;
sporotrichosis; chromoblastomycosis; phaeohyphomycosis; and
disseminated sporotrichosis.
[0145] Examples of superficial infections, which can be prevented
or treated using a pharmaceutical composition of the invention
include: ring worm; athlete's foot; and tinea unguium (nail
infection).
[0146] Examples of diseases or conditions which are caused by fungi
or where fungi exacerbate an allergic response, and which can be
prevented or treated using a pharmaceutical composition of the
invention include allergic bronchopulmonary aspergillosiis (ABPA);
asthma, Severe asthma with Fungal Sensitisation (SAFS), fungal
colonization of cystic fibrosis, rhinosinusitis and sinusitis. For
instance, the disease may be caused by a fungal sensitisation, or
the disease may be Allergic Bronchopulmonary Aspergillosis (ABPA)
or asthma.
[0147] The pharmaceutical compositions described herein can be
administered in combination with a second antifungal agent.
Preferably, the pharmaceutical composition is administered
separately from or successively with the second antifungal agent.
For example, the composition of the invention and the second
antifungal agent may be provided as a kit. The kit may thus
comprise a composition of the invention and a second antifungal
agent.
[0148] The second antifungal agent can be any suitable antifungal
agent that the skilled person would judge to be useful in the
circumstances. For example, any of the conditions described herein
can be treated in his manner.
[0149] Particularly suitable classes of antifungal agents include
azoles, polyenes, purine nucleotide inhibitors, pyrimidine
nucleotide inhibitors, mannan inhibitors, protein elongation factor
inhibitors, chitin synthase inhibitors, Beta-glucan synthase
inhibitors, echinocandins, allylamines, anti-HSP90 antibodies,
bactericidal/permeability inducing protein products and polyoxins.
Other suitable antifungal agents which do not fall within the
classes above include the compounds
5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborale (AN269),
5-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborale (AN2718) and
icofungipen.
[0150] For instance, the second antifungal agent may be selected
from the group consisting of azoles, polyenes, purine nucleotide
inhibitors, pyrimidine nucleotide inhibitors, mannan inhibitors,
protein elongation factor inhibitors, echinocandins, allylamines,
anti-HSP90 antibodies, bactericidal/permeability inducing protein
products or polyoxins, or one of the compounds
5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborale (AN269),
5-chloro-1,3-dihydro-1-hydroxy-2,1-benzoxaborale (AN2718),
icofungipen, VT116 or SCY078.
[0151] VT116 is 2-Pyridineethanol,
.alpha.-(2,4-difluorophenyl)-.beta.,.beta.-difluoro-.alpha.-(1H-tetrazol--
1-ylmethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-, (.alpha.R)-,
##STR00005##
and SCY078 078 (aka MK-3118) is a semi-synthetic derivative of
enfumafungin,
4H-1,4a-Propano-2H-phenanthro[1,2-c]pyran-7-carboxylic acid,
15-[(2R)-2-amino-2,3,3-trimethylbutoxy]-8-[(1R)-1,2-dimethylpropyl]-
-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-14-[-
5-(4-pyridinyl)-1H-1,2,4-triazol-1-yl]-,
(1S,4aR,6aS,7R,8R,10aR,10bR,12aR,14R,15R):
##STR00006##
[0152] Preferred azoles are clotrimazole, econazole, bifonazole,
butoconazole, fenticonazole, fluconazole, isoconazole,
itraconazole, ketoconazole, miconazole, oxiconazole, sertaconazole,
sulconazole, tioconazole, isavuconazole, ravuconazole,
posaconazole, terconazole and voriconazole, luliconazole. Preferred
echinocandins are anidulafungin, caspofungin micafungin and
biafungin. Preferred allylamines are terbinafine, butenafine,
amorolfine and naftifine. Preferred polyenes are amphotericin B and
nystatin. A preferred example of a purine or pyrimidine nucleotide
inhibitor is flucytosine. A preferred mannan inhibitor is
pradamicin. A preferred protein elongation factor inhibitor is
sordarin and analogues thereof. A preferred polyoxin is nikkomycin
Z.
[0153] Particularly preferred second antifungal agents are
caspofungin, micafungin, anidulofungin, amphotericin B,
voriconazole, posaconazole, isavuconazole, fluconazole and
itraconazole.
Synthesis
[0154] The compound of Formula I is
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide, or a pharmaceutically
acceptable salt thereof.
##STR00007##
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide
[0155] One synthetic route to the compound of Formula I is
described herein. In general terms, the compound of Formula I may
be synthesised by reacting a compound of formula (II), with a
compound of formula (III). Typically the reaction takes place in
the presence of an organic solvent and a base. Preferably the
solvent is dichloromethane or tetrahydrofuran and the base is
triethylamine or pyridine. Typically the reaction is carried out at
0.degree. C. initially while the reagents are added and then
stirred at room temperature until the reaction is complete. The
compound of formula (III) is typically available from commercial
sources or can be prepared by known methods.
##STR00008##
[0156] The compound of formula (II) may be prepared by reacting a
compound of formula (IV), with preferably oxalyl chloride.
Typically the reaction takes place in an organic solvent.
Preferably, the solvent is dichloromethane. Typically, the reaction
is carried out at 0.degree. C. initially while the reagents are
added and then stirred at room temperature until the reaction is
complete.
##STR00009##
[0157] All of the starting materials referred to in the reactions
described above are available from commercial sources or can be
prepared by analogy with known methods.
[0158] The following examples illustrate the invention but are not
intended to limit the scope of the invention. In this regard, it is
important to understand that the particular assays used in the
Examples section are designed only to provide an indication of
anti-fungal activity. There are many assays available to determine
such activity, and a negative result in any one particular assay is
therefore not determinative.
EXAMPLES
Example 1: Synthesis of the Compounds of Formula I
(2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl-
)piperazin-1-yl)phenyl)-2-oxoacetamide)
[0159] The synthesis of the compound of Formula I is described in
the international patent application having application number
PCT/GB2015/053546. Information relating to the synthesis of the
compound of Formula I is incorporated by reference. The following
Example is reproduced from that patent application.
[0160] The synthetic scheme below provides a method of synthesis
of:
##STR00010## ##STR00011##
2-Hydroxyimino-3-oxo-3-phenyl propionic acid ethyl ester (A)
##STR00012##
[0161] A solution of sodium nitrite (1.07 Kg, 45.62 mol) in water
(4 L) was added slowly to a solution of ethyl benzoyl acetate (2
Kg, 10.41 mol) in glacial acetic acid (6 L), at 0-10.degree. C.
over a period of 2 h. The product started precipitating during the
course of addition. The reaction mass was warmed to room
temperature and stirred for a further 1 h. Water (2.5 L) was added
and the mixture stirred for a further 1 h. Filtered under suction,
washed with water (2 L). The solid was dissolved in chloroform (8
L) and washed with water (2.times.500 mL), brine solution
(2.times.500 mL), dried over anhydrous sodium sulfate and
concentrated in vacuo to dryness to afford 2.0 Kg (86%) of
2-hydroxyimino-3-oxo-3-phenyl propionic acid ethyl ester A as a
white solid. [TLC system: Ethyl acetate:Pet ether (3:7); R.sub.f
value: 0.28].
5-Methyl-3-phenyl-1H-pyrrole-2,4 dicarboxylic acid diethyl ester
(B)
##STR00013##
[0162] A mixture of ethyl acetoacetate (329 g, 2.53 mol), zinc dust
(443 g, 6.78 mol) and anhydrous sodium acetate (463 g, 5.65 mol) in
glacial acetic acid (800 mL) were heated to 60.degree. C. A
solution of A (500 g, 2.26 mol) in glacial acetic acid (1.5 L) was
added in three portions under vigorous stirring over a period of
.about.1 h. The temperature shot up to about 93.degree. C. during
the addition. The reaction mixture was maintained at 60-75.degree.
C. for 3 h. Additional zinc dust (221 g, 3.39 mol) was added to the
reaction mass over 15 min and the mixture was stirred at
60-75.degree. C. for 1 h, cooled to room temperature and filtered
the solids. The filtrate was evaporated in vacuo and the residue
was co-distilled with toluene (2.times.500 mL). Water (5 L) and
ethyl acetate (1 L) were added to the residue and stirred till two
clear layers were obtained. The organic layer washed successively
with water (2.times.500 mL), saturated bicarbonate solution
(2.times.500 mL), brine (2.times.500 mL) dried over anhydrous
sodium sulfate and concentrated to give 360 g of crude gummy
product. This was stirred with a mixture of dichloromethane in pet
ether (200 mL: 1200 mL; 1:6) at room temperature for 15 min,
filtered and washed with pet ether (100 mL) to afford 250 g (36%)
of 5-methyl-3-phenyl-1H-pyrrole-2,4 dicarboxylic acid diethyl ester
B as off-white solid. [TLC system: ethyl acetate:Pet ether (3:7);
R.sub.f value: 0.45]. Similarly 1.5 Kg (500 g.times.3) of A was
converted to 500 g [245 g (36%)+255 g (37%)+250 g (36%)] of B in
three batches.
1, 5-Dimethyl-3-phenyl-1H-pyrrole-2,4-dicarboxylic acid diethyl
ester (C)
##STR00014##
[0163] A solution of B (1 Kg, 3.322 mol) in dry tetrahydrofuran (4
L) was added to slurry of sodium hydride (60% w/w; 254 g, 6.644
mol) in dry tetrahydrofuran (4 L) at 0.degree. C. over 1 h. The
reaction mass was warmed to room temperature and stirred for 1 h
and again cooled to 0.degree. C. Methyl iodide (517 mL; 8.305 mol)
was added over 1/2 h and the reaction mixture stirred at room
temperature for 18 h. Quenched with ice-water (100 mL) and 1N
hydrochloric acid (2 L) was added. The organic layer was separated
and the aqueous layer was extracted with dichloromethane
(2.times.500 mL). The combined organic layers were washed
successively with brine (2.times.200 mL), dried over anhydrous
sodium sulfate and concentrated to dryness to afford 950 g (91%) of
1, 5-dimethyl-3-phenyl-1H-pyrrole-2, 4-dicarboxylic acid diethyl
ester C as a yellow solid [TLC system: ethyl acetate:Pet ether
(3:7); R.sub.f value: 0.56].
1, 5-Dimethyl-3-phenyl-1H-pyrrole-2,4-dicarboxylic acid (D)
##STR00015##
[0164] A solution of sodium hydroxide (1.21 Kg, 30.25 mol) in water
(3.6 L) was added to a solution of C (950 g, 3.025 mol) in ethanol
(5 L) and heated at reflux for 15 h. Ethanol was evaporated under
reduced pressure, the residue was diluted with water (1 L) and
chilled to 0.degree. C. Concentrated hydrochloric acid (2 L) was
slowly added to adjust pH to .about.2, while maintaining
temperature below 10.degree. C. and stirred for 1 h. The
precipitated solid was filtered, washed with water (1 L) and pet
ether (1 L) and dried under vacuum at 60.degree. C., to afford 550
g (70%) of 1,5-Dimethyl-3-phenyl-1H-pyrrole-2,4-dicarboxylic acid D
as a white solid. [TLC system: ethyl acetate:Pet ether (3:7);
R.sub.f value: 0.15].
1, 2-Dimethyl-4-phenyl-1H-pyrrole (E)
##STR00016##
[0165] A suspension of E (550 g, 2.123 mol) in ethanolamine (1.5 L)
was heated to 175.degree. C. (under N.sub.2) and maintained for 1
h. The reaction mixture was cooled to room temperature, diluted
with water (500 mL) and extracted with ethyl acetate (3.times.200
mL). The combined organic layers were washed successively with
water (2.times.100 mL) and brine (2.times.100 mL), dried over
anhydrous sodium sulfate and concentrated in vacuo below 40.degree.
C. to give a crude product. Flash chromatography over neutral
alumina using 5% ethyl acetate in pet ether as eluent afforded 280
g (77%) of 1,2-dimethyl-4-phenyl-1H-pyrrole E, as a white solid.
[TLC system: ethyl acetate:Pet ether (3:7); R.sub.f value:
0.75].
(1, 5-Dimethyl-3-phenyl-1H-pyrrol-2-yl)-oxo-acetyl chloride (F)
##STR00017##
[0166] Oxalyl chloride (116 mL, 1.286 mol) was added slowly to a
cooled solution of E (250 g, 1.169 mol) in dry dichloromethane
(3.times.200 mL) at 0.degree. C. The reaction mixture was warmed to
room temperature and stirred for 1 h. The solvent was evaporated to
dryness in vacuo to afford 340 g (89%) of
1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-oxo-acetyl chloride F as a
brown oily liquid. [TLC system: ethyl acetate:Pet ether (3:7);
R.sub.f value: 0.65]
4-Nitro phenyl piperazine (G)
##STR00018##
[0167] A solution of 1-chloro-4-nitro benzene (650 g, 4.140 mol) in
diglyme (1 L) was added to a solution of piperazine (2.84 Kg, 33.12
mol) in diglyme (500 mL) at 100.degree. C. and the resultant mass
was stirred at 100.degree. C. for 6 h. The mixture was cooled to
40-45.degree. C., water (5 L) was added; warmed to room temperature
and stirred for 1 h. The precipitated solid was filtered, washed
with water (1 L), pet ether (500 mL) and dried to give 700 g (81%)
of 4-nitro phenyl piperazine G as yellow colour solid. [TLC system:
Ethyl acetate:pet ether (3:7); R.sub.f value: 0.70].
5-Fluoro-2-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine (H)
##STR00019##
[0168] 2-Chloro-5-fluoropyrimidine (281 g, 2.12 mol) was added to
suspension of 4-nitro phenyl piperazine G (400 g, 1.93 mol) and
potassium carbonate (532 g, 3.85 mol) in diglyme (2.5 L), the
resulting mixture was stirred at 100.degree. C. for 6 h. On
completion the mixture was cooled to 0.degree. C. and filtered, the
solid was taken in water (5 L) and stirred for 30 mins. The
suspension was filtered, the solid cake was washed with water (1
L), pet ether (1 L) and dried under vacuum to afford 500 g (85%) of
5-fluoro-2-[4-(4-nitro-phenyl)-piperazin-1-yl]-pyrimidine H as
yellow colour solid. [TLC system: Ethyl acetate:pet ether (3:7);
R.sub.f value: 0.70].
4-[4-(5-Fluoro-pyrimidin-2-yl)-piperazin-1-yl]-phenyl amine (I)
##STR00020##
[0169] A solution of sodium dithionite (1.27 Kg, 7.32 mol) in water
(6 L) was added to a suspension of H (500 g, 1.83 mol) and sodium
bicarbonate (614 g, 7.32 mol) in methanol (6 L) at 65.degree. C.
The resultant mixture was stirred at 65.degree. C. for 2 h. The
reaction mass was cooled to 10-15.degree. C. and filtered. The
residue was partitioned between water (2 L) and ethyl acetate (5
L), the organic layer was washed with water (2 L), brine (2 L) and
dried over anhydrous sodium sulfate. Concentrated in vacuo to
afford 290 g (64%) of
4-[4-(5-fluoro-pyrimidin-2-yl)-piperazin-1-yl]-phenyl amine I as
solid. [TLC system: Methanol:Chloroform (1:9); R.sub.f value:
0.50].
2-(1,5-Dimethyl-3-phenyl-1H-pyrro-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)--
piperazin-1-yl]-phenyl}-2-oxo-acetamide
##STR00021##
[0170] A solution of F (332 g, 1.27 mol) in dichloromethane (3 L)
was added to a stirred solution of I (290 g, 1.06 mol) and
triethylamine (294 mL, 2.12 mol) in dichloromethane (3 L) at
0.degree. C. The reaction mixture was warmed to room temperature
and stirred for 30 min. The reaction mixture was quenched with
water and extracted with dichloromethane (6.times.500 mL). The
combined organic layers were washed successively with saturated
sodium bicarbonate solution (1.5 L), water (1 L), brine (1.5 L) and
finally dried over anhydrous sodium sulfate. The organic layer was
stirred with neutral alumina (1 Kg) at room temperature for 30 min
and filtered. The filtrate was concentrated in vacuo to give the
crude compound which on washing with diethyl ether (300 mL) and
followed by trituration with ethanol (3 L) at 80.degree. C. for 1 h
and cooled to room temperature, filtered, washed with ethanol (500
mL) followed by hexane (200 mL) and dried to give 340 g (64%) of
2-(1,5-dimethyl-3-phenyl-1H-pyrro-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl--
piperazin-1yl]-phenyl}-2-oxo-acetamide as yellow color solid. [TLC
System: Ethyl acetate:Pet ether (1:1); R.sub.f value: 0.65]. NMR
data for 2-(1,
5-Dimethyl-3-phenyl-1H-pyrro-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)-pipe-
razin-1-yl]-phenyl}-2-oxo-acetamide (.sup.1H NMR (400 MHz,
CDCl.sub.3)) are provided in FIG. 1. The signal was detected in the
MS spectrum at 499.1 [M+H].sup.+.
Example 2: Anti-Fungal Activity of the Compound of Formula I
[0171] Data demonstrating that
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)-
piperazin-1-yl)phenyl)-2-oxoacetamide inhibits the growth of a wide
variety of fungi are presented in the international patent
application having application number PCT/GB2015/053546.
Information relating to the biological activity of the compound of
Formula I is incorporated by reference.
[0172] PCT/GB2015/053546 describes experiments comparing the
antifungal activity of the compound of Formula I to various
reference compounds. The experiments described in PCT/GB2015/053546
show that the compound of Formula I inhibits growth of fungal
organisms with MIC (minimum inhibitory concentrations; i.e. the
lowest drug concentration that inhibits growth of an organism by
>80% compared with a drug free control) as follows:
TABLE-US-00001 Band MIC/mg/L A MIC .ltoreq. 0.005 B 0.005 < MIC
.ltoreq. 0.01 C 0.01 < MIC .ltoreq. 0.02 D 0.02 < MIC
.ltoreq. 0.04 E 0.04 < MIC .ltoreq. 0.06 F MIC .gtoreq. 0.06 MIC
band Organism (RPMI medium) A. niger C A. fumigatus C A. terreus A
A. flavus B A. terreus 49 A A. fumigatus 210 C S. apiospermum 13486
D S. apiospermum 15848 D S. apiospermum 451 B S. apiospermum 4883 C
S. apiospermum 7935 C S. apiospermum 8353 B S. prolificans 18389 C
S. prolificans 206 D S. prolificans 6322 D S. species 15849 E S.
apiospermum 13486 D S. prolifican 201 D S. prolifican 13486 D S.
prolifican 7935 C S. prolifican 15848 D S. prolifican 8353 B S.
prolifican 451 B S. prolifican 4883 C S. prolifican 15849 E S.
prolifican 1121 A S. apiospermum 1124 A
[0173] The compound of Formula 1 showed also good antifungal
activity against S. dehoogii, S. boydii and S. aurantiacum.
[0174] PCT/GB2015/053546 also describes experiments in which the
compound of Formula I was tested in vivo in a mouse model. The data
in that application shows that the compound of Formula I gives
excellent efficacy in murine models of invasive aspergillosis, and
that the compound of Formula I is able to reduce galactomannan
indices in A. fumigatus infected mice. The compound of Formula I is
also able to increase survival of mice infected with Lomentospora
prolificans FMR 3569 relative to control experiments using the anti
fungal agent voriconazole
[0175] In the in vivo experiments described in PCT/GB2015/053546,
the compound of Formula I was administered orally by gavage. The
administration of the compound of Formula I in PCT/GB2015/053546
was not achieved using the formulations of the present
invention.
Example 3: PK Experiments--In Vivo Rodent Experiments to Determine
Preferred Oral Formulations of the Compound of Formula I
[0176] Various formulations were investigated in in vivo PK studies
in rats to determine the optimal oral formulation for dosing to
animals and humans.
[0177] The compound of Formula I was administered to rats by IV at
a dosage of 10 mg/kg. The vehicle comprised 15% hydroxypropyl beta
cyclodextrin (Kelptose HPB parenteral grade), 5% DMSO and water for
injection. The formulation was filtered using a .ltoreq.0.22 .mu.m
polyethersulfone (PES) membrane filter prior to use. The dose
volume administered was 5 mL/kg. 0.2 mL blood samples from the
sublingal vein under isoflurane anaesthesia were obtained 5 minutes
after IV administration and stored in EDTA. Plasma was separated by
centrifugation (1500.times.g, 10 mins, ca. 4.degree. C.) and was
frozen at -70.degree. C. prior to analysis. Analysis to calculate
plasma concentration of the compound of Formula I was conducted by
LC-MS/MS. Typical AUC values (AUC.sub.IV) of 13500 nghr/ml were
recorded, corresponding to 100% bioavailability (by definition).
The AUC.sub.IV value was subsequently used to calculate the
bioavailability of example oral formulations as described
above.
Formulation 1
[0178] A crystalline sample of the compound of Formula I was
formulated in PEG300. The formulation was dosed p.o. (gavage) to
rats at 10 mg/kg (dose volume=5 mL/kg). 0.2 mL blood samples from
the sublingal vein under isoflurane anaesthesia were obtained 15
minutes after oral administration and stored in EDTA. Samples were
then taken 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose. PK data
(determined as for the IV formulation) revealed AUC.sub.PO (0-24
hours) of 6610 nghr/ml, corresponding to a bioavailability (F) of
49%.
Formulation 2
[0179] A crystalline sample of the compound of Formula I was
formulated in a solution of 90% PEG300:10% TPGS
(d-.alpha.-Tocopheryl polyethylene glycol 1000 succinate). TPGS is
a known bioavailability enhancer that acts as a drug solubiliser
and a precipitation inhibitor and was incorporated as its presence
has proved beneficial in formulations of other insoluble compounds.
When dosed p.o. as a solution in a vehicle consisting of
PEG300/TPGS at a dose of 150 mg/kg (formulation concentration; 15
mg/mL), the AUC.sub.PO (0-24 hours) values in male and female
fasted rats were 34271 nghr/ml and 76963 nghr/ml respectively,
equivalent to bioavailability values of 17% and 38% respectively.
However, when this formulation was administered for extended
periods, side effects of diarrhea were observed indicating that the
formulation would be unsuitable for clinical administration.
Formulations 3 and 4
[0180] A crystalline sample of the compound of Formula I was
micronised by jet milling to a final particle size of D(v0.9)=6.7
.mu.m, and subsequently suspended in a mixture of HPMC (75%) and
SDS (sodium dodecyl sulphate 0.05%). This formulation (formulation
3) was dosed p.o. to male and female rats at 150 mg/kg. PK
experiments gave AUC.sub.PO (0-24 hours) values of 9004 nghr/ml and
26286 nghr/ml for male and female rats respectively, equivalent to
a bioavailability of 4.5% and 13% respectively.
[0181] The compound of Formula I was nanonised in a similar manner
and formulated in HPMC/SDS as for formulation 3 (to give
formulation 4), and was administered to male and female rats p.o.
PK experiments gave AUC.sub.PO (0-24 hours) values of 17785 nghr/ml
and 40272 nghr/ml in male and female rats respectively, equivalent
to a bioavailability of 9% and 20%, respectively.
[0182] Neither formulation 3 nor formulation 4 yielded adequate
bioavailability of the compound of Formula I. Furthermore, PK
experiments revealed that the time for maximum plasma concentration
of the compound of formula I (T.sub.max) was significantly delayed
suggesting delayed/incomplete absorption.
Formulation 5
[0183] The compound of Formula I was formulated with hydroxypropyl
methyl cellulose acetate succinate (HPMCAS) (10% w/w compound of
Formula I:90% HPMCAS). The formulation was spray-dried from a
solution of 3:1 v/v dichloromethane:methanol. The formulation was
administered p.o. to male and female rats at a dose of 10 mg/kg in
20 mM phosphate buffer (suspension). PK experiments gave AUC.sub.PO
(0-24 hours) values of 13202 nghr/ml and 27774 nghr/ml in male and
female rats, respectively, indicating a bioavailability >95% in
both sexes.
[0184] Unlike formulation 2, formulation 5 was tolerated by both
male and female rats with no GI tract disturbances. This allowed
toxicological studies to be performed over 1-3 months. Formulation
5 was well tolerated by both male and female rats over this
period.
Comparison of Formulation 2 and Formulation 5
[0185] A comparison of the results of PK experiments conducted
using formulations 2 and was conducted at equivalent dosages (50
mg/kg) dosed p.o. twice daily (BID) for 28 days. These data show
that better exposure was obtained using formulation 5 as compared
to formulation 2, with the further benefit of the absence of
negative effects on the GI tract associated with formulation 2.
TABLE-US-00002 Cmpd of AUC.sub.PO ng hr/ml Formulation Formula
I/Dose Sex Day 1 Day 28 2 50 mg/kg Male 19880 23280 Female 39400
92390 5 50 mg/kg Male 28860 44880 Female 43440 149700
Example 4: PK Experiments--In Vivo Cynomolgus Monkey Experiments to
Determine Preferred Oral Formulations of the Compound of Formula
I
[0186] Various formulations were investigated in in vivo PK studies
in cynomolgus monkeys to determine the optimal oral formulation for
dosing to animals and humans.
[0187] The compound of Formula I was administered to male and
female cynomolgus monkeys by IV at a dosage of 10 mg/kg. The IV
formulation was as described in Example 3. PK experiments gave
typical AUC values (AUC.sub.IV) of 18000 nghr/ml. The AUC.sub.IV
value was subsequently used to calculate the bioavailability of
example oral formulations as described above.
Formulation 2
[0188] Studies were conducted using Formulation 2 as described
above. The compound of Formula I was administered p.o. to male and
female cynomolgus monkeys at a dose level of 10 mg/kg. (dose volume
5 mL/kg). 2 mL blood samples were obtained 5 minutes via femoral
puncture (vein/artery) into commercially available K.sub.2EDTA
tubes using 23 G needles coupled to a suitable syringe. Samples
were taken 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after
administration of the formulation. Blood samples were kept on ice
until centrifugation at 1600.times.g (10 mins, ca. 5.degree. C.) to
separate plasma. Analysis to calculate plasma concentration of the
compound of Formula I was conducted by LC-MS/MS. PK experiments
gave AUC.sub.PO (0-24 hours) values of 14915 nghr/ml and 8192
nghr/ml in male and female subjects, respectively, indicating a
bioavailability of 83% and 46% in males and females,
respectively.
[0189] Unfortunately, gastrointestinal problems (notably diarrhea)
as observed in experiments in rats (see Example 3 above) were noted
also for cynomolgus monkeys. Studies of 1 month duration with the
PEG/TPGS vehicle showed that diarrhea was a major problem despite
the use of anti-diarrheal medication (Diosmectite; "Smecta", 1 bag
(3 g) per animal 4 hours post-dose). These studies showed that
despite promising oral bioavailability of the compound of Formula
I, formulation 2 was unlikely to be suitable for clinical
administration.
Formulation 5
[0190] Studies were conducted using Formulation 5 as described in
Example 3. The compound of Formula I was administered p.o. to male
and female cynomolgus monkeys at a dose level of 10 mg/kg (dose
volume: 5 mg/kg; formulation concentration 2 mg/mL of the compound
of Formula I, corresponding to 20 mg/mL of the spray-dried
particles)
[0191] The particles produced as described for Formulation 5 were
suspended in different buffer compositions/volumes. PK experiments
as described above gave AUC.sub.PO (0-24 hours) values as
follows:
TABLE-US-00003 AUC.sub.PO (0-24 hours)/ Sex Dose/mg/kg Vehicle ng
hr/ml Male 10 10 ml/20 mM phosphate buffer 16804 Female 10 10 ml/20
mM phosphate buffer 20871 Male 10 5 ml/40 mM phosphate buffer 26112
Female 10 5 ml/40 mM phosphate buffer 12684
[0192] As can be seen, when low buffer salt concentrations (20 mM)
and high buffer volumes (10 mL) were used, or when low buffer
volumes (5 mL) but higher buffer strengths (40 mM) were used, high
AUC.sub.PO (0-24 hours) values were observed. Under these
conditions, bioavailability >90% was observed using 10 ml of 20
mM phosphate buffer and bioavailability >70% using 5 ml of 40 mM
phosphate buffer. (Slight variation in the results obtained using
female subjects dosed with 5 ml of 40 mm buffer was observed which
accounts for the apparently poorer bioavailability in this subject
group).
[0193] Studies carried out with formulation 5 at a variety of doses
in cynomolgus monkeys revealed a complete lack of gastrointestinal
side effects; the formulation is thus much better tolerated in
mammals than formulation 2 described above. High drug levels were
obtained after repeat dosing, with improved dose proportionality
observed between doses.
Comparison of Formulation 2 and Formulation 5
[0194] A comparison of the results of PK experiments conducted
using formulations 2 and was conducted at equivalent dosages (50
mg/kg) dosed p.o. twice daily (BID) for 14 days. These data show
that better exposure was obtained using formulation 5 as compared
to formulation 2, with the further benefit of the absence of
negative effects on the GI tract associated with formulation 2.
TABLE-US-00004 Cmpd of AUC.sub.PO ng hr/ml Formulation Formula
I/Dose Sex Day 1 Day 14 2 50 mg/kg Male 50460 59590 Female 32160
91250 5 50 mg/kg Male 57200 86745 Female 48810 110500
The above data obtained in both rat and cynomolgus monkey shows
that when the compound of Formula I is formulated in the form of
Formulation 5 described above, excellent pharmacokinetics in both
rat and cynomolgus monkey is observed. The formulation is well
tolerated and is especially beneficial compared with solvent based
vehicles such as PEG/TPGS due to the absence of observed GI
symptoms which would be likely to require intervention with
antidiarrheal treatments if used clinically. There is also better
dose proportionality in AUC and Cmax using this formulation
compared with solvent based formulations.
Formulation 6
[0195] The compound of Formula I was formulated in a solution of
25% DMSO:75% PEG300 (% v/v) (concentration of compound in vehicle:
2 mg/mL). The formulation was administered p.o. to male and female
cynomolgus monkeys at a dose of 10 mg/kg (administered dose volume:
5 mL/kg). 2 mL blood samples were obtained 5 minutes via femoral
puncture (vein/artery) into commercially available K.sub.2EDTA
tubes using 23 G needles coupled to a suitable syringe. Samples
were taken 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after
administration of the formulation. Blood samples were kept on ice
until centrifugation at 1600.times.g (10 mins, ca. 5.degree. C.) to
separate plasma. Analysis to calculate plasma concentration of the
compound of Formula I was conducted by LC/MS-MS. PK experiments
gave AUC.sub.PO (0-24 hours) values of 2900 nghr/ml and 1480
nghr/ml in male and female subjects, respectively, indicating a
bioavailability of 16% and 8% in males and females,
respectively.
Formulation 7
[0196] A lipid based formulation (Catalent) intended to assist
solubilisation (and thus increase bioavailability) of the compound
of Formula I was developed and tested in cynomolgus monkeys as
described above. This formulation was administered p.o. to male and
female cynomolgus monkeys at a dose of 10 mg/kg. PK experiments
gave AUC.sub.PO (0-24 hours) values of 3282 nghr/ml and 1924
nghr/ml in males and females, respectively, indicating very low
bioavailability values of 18% and 11%, respectively.
Example 5: PK Experiments--In Vivo Human Trials
[0197] Studies were conducted using a spray-dried formulation in
accordance with the compositions of the inventions. The formulation
consisted of 20% of the compound of Formula I/80% HPMCAS suspended
in 20 mM phosphate buffer as described for formulation 5 in Example
4. Blood samples were taken following dosage of the formulation and
plasma concentrations of the compound of Formula I were determined
as described above.
[0198] Initial experiments were conducted to determine the effect
of varying the administered dose of the formulation. Results are
presented in the following Table.
TABLE-US-00005 Dose T.sub.max.sup.# C.sub.max AUC.sub.0-12
AUC.sub.0-24 AUC.sub.0-t AUC.sub.0-.infin. t.sub.1/2 CL/F
C.sub.12.sup.+ C.sub.24.sup.+ MRT V.sub.ss/F (mg/kg) (h) (.mu.g/mL)
(.mu.g h/mL) (h) (mL/h)/kg (.mu.g/mL) (h) (L/kg) 2 1.25 0.913 4.36
6.84 11.68 12.18 23.3 190 0.154 0.205 29.5 5.23 4 2.5 2.30 13.30
19.24 40.51 46.67 37.0 112 0.552 0.547 47.6 4.45 6 3.5 3.67 19.85
32.09 64.72 69.44 29.2 95 0.814 1.018 40.7 3.79 8 4.0 5.32 28.38
41.76 81.86 88.20 32.3 94 1.290 1.254 44.1 4.05 10 3.0 5.79 28.80
44.14 79.21.sup.$ 99.14 31.1 111 1.352 1.338 42.0 4.34 .sup.#Median
values. .sup.+Concentrations at 12 and 24 h post-dose (for
potential repeat dose purposes). .sup.$AUC.sub.0-t values only from
0-72 h at present to prevent unblinding.
In the preceding table: T.sub.max=time of observed maximum
concentration of the compound of Formula I; C.sub.max=observed
maximum concentration; AUC.sub.A-B=area under the PK plasma curve
vs time curve, wherein A is time=0 hours and B=time to which curve
determined; t.sub.1/2=apparent terminal elimination half-life;
CL=clearance; C.sub.n (n=12, 24)=concentration of compound of
Formula I at indicated time point; MRT=mean residence time;
V.sub.SS=volume of distribution at steady-state
[0199] Plots of C.sub.max and AUC.sub.0-.infin. as a function of
administered dose revealed good dose proportionality (C.sub.max:
proportionality=1.18; AUC: proportionality=1.30) as shown in FIGS.
1 to 3. Excellent bioavailability of ca. 95%+ was observed.
* * * * *